Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07056309 · ClinicalTrials.gov registry record · Phase 1
A Study of Remternetug (LY3372993) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07056309 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT07056309, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.
Interventions
- DRUG Remternetug (Test)
- DRUG Remternetug (Reference)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07056309
The ClinicalTrials.gov registry entry for NCT07056309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Remternetug (Test) is the first listed.
NCT07056309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07056309 about?
NCT07056309 is a clinical study titled "A Study of Remternetug (LY3372993) in Healthy Participants". The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes th...
What is the current status of trial NCT07056309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-06-24. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT07056309?
The interventions under investigation include: Remternetug (Test) (DRUG), Remternetug (Reference) (DRUG).
Who is sponsoring clinical trial NCT07056309?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.